The New England Journal of Medicine tells MassDevice.com that its editors are reviewing a 2010 study published by the journal on the effectiveness of CareFusion’s ChloraPrep in fighting surgical site infections after questions arise over financial links between the company and the study’s lead author. Editors at the New England Journal of Medicine are reviewing the publication of data from a 2010 study on CareFusion’s (NYSE:CFN) ChloraPrep antiseptic, prompted by a federal complaint that called the trial “off label” and “invalid,” the journal told MassDevice.com today.
Help employers find you! Check out all the jobs and post your resume.
